why choose us

First received: September 14, 2023

Clinical Trial: Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Head Neck

Study Type: INTERVENTIONAL


Official Title: Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

Brief Summary: To learn if magrolimab, along with a combination of commercially-available drugs (cetuximab, pembrolizumab, and docetaxel) can help to control HNSCC in combination with other drugs.The safety of magrolimab will also be studied.

Read more